Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target.

Autor:	Hong J; Department of Physiology, Daegu Catholic University School of Medicine, Daegu 42472, Korea.; Laboratory of Cancer Immunometabolism, National Cancer Institute, Frederick, MD 21702, USA., Jhun H; Technical Assistance Center, Korea Food Research Institute, Wanju 55365, Korea., Choi YO; Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul 05029, Korea., Taitt AS; Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul 05029, Korea., Bae S; Department of Bioequivalence Division for Drug Evaluation, Ministry of Food and Drug Safety, Cheongju 28159, Korea., Lee Y; Department of Medicine, Pusan Paik Hospital, College of Medicine, Inje University, Busan 47392, Korea., Song CS; College of Veterinary Medicine, Konkuk University, Seoul 05029, Korea., Yeom SC; Graduate School of International Agricultural Technology, Seoul National University, Pyeongchang 25354, Korea., Kim S; Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul 05029, Korea.; College of Veterinary Medicine, Konkuk University, Seoul 05029, Korea.; Veterinary Science Research Institute, Konkuk University, Seoul 05029, Korea.
Jazyk:	angličtina
Zdroj:	Immune network [Immune Netw] 2021 Feb 19; Vol. 21 (1), pp. e8. Date of Electronic Publication: 2021 Feb 19 (Print Publication: 2021).
DOI:	10.4110/in.2021.21.e8
Abstrakt:	The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target. Competing Interests: Conflict of Interest: The authors declare no potential conflicts of interest. (Copyright © 2021. The Korean Association of Immunologists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu